Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22169010 | 0.92 | CYP19A1 (0.36) | CYP19A1ESR1ESR2 | |
| SCHEMBL19251240 | 0.91 | CYP19A1 (0.42) | CYP19A1ESR1ESR2 | |
| SCHEMBL19251062 | 0.89 | CNR2 (0.36) | CYP19A1ESR1ESR2 | |
| SCHEMBL18382253 | 0.87 | CYP19A1 (0.38) | CYP19A1ESR1ESR2 | |
| SCHEMBL22007446 | 0.85 | CYP19A1 (0.37) | CYP19A1 | |
| SCHEMBL19251056 | 0.84 | CNR2 (0.38) | CYP19A1 | |
| SCHEMBL18935500 | 0.84 | CNR2 (0.38) | CYP19A1 | |
| SCHEMBL18909511 | 0.84 | CYP19A1 (0.36) | CYP19A1ESR1ESR2 | |
| SCHEMBL19251185 | 0.84 | CNR2 (0.38) | CYP19A1 | |
| SCHEMBL19251174 | 0.84 | CNR2 (0.38) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP19A1 293/4885ESR1 2830/4885ESR2 3452/4885 |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | DRD3, DRD2, DRD4 | CYP19A1 580/4885ESR1 252/4885ESR2 1045/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CYP19A1 867/4885ESR1 1662/4885ESR2 2553/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CYP19A1 867/4885ESR1 1662/4885ESR2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.